Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
- 30 April 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (9) , 4446-4456
Abstract
In our pursuit of developing a novel and potent potassium-competitive acid blocker (P-CAB), we synthesized pyrrole derivatives focusing on compounds with low log D and high ligand-lipophilicity efficiency (LLE) values. Among the compounds synthesized, the compound 13e exhibited potent H+,K+-ATPase inhibitory activity and potent gastric acid secretion inhibitory action in vivo. Its maximum efficacy was more potent and its duration of action was much longer than those of proton pump inhibitors (PPIs). Therefore, compound 13e (1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate, TAK-438) was selected as a drug candidate for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer, and other acid-related diseases.Keywords
This publication has 29 references indexed in Scilit:
- N-(2-Hydroxyethyl)-N,2-dimethyl-8-{[(4 R)-5-methyl-3,4-dihydro-2 H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a Novel, Potent, and Selective Acid Pump Antagonist for the Treatment of Gastroesophageal Reflux DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPaseBiochemical Pharmacology, 2007
- Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseasesPharmacology & Therapeutics, 2005
- Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next?Alimentary Pharmacology & Therapeutics, 2005
- Proton pump inhibitors: update on their role in acid-related gastrointestinal diseasesInternational Journal Of Clinical Practice, 2005
- Novel approaches to the pharmacological blockade of gastric acid secretionExpert Opinion on Investigational Drugs, 2005
- Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in ratsBiopharmaceutics & Drug Disposition, 1998
- Differences in the Antisecretory Actions of the Proton Pump Inhibitor AG-1749 (Lansoprazole) and the Histamine H2-Receptor Antagonist Famotidine in Rats and DogsThe Japanese Journal of Pharmacology, 1991
- Gastric H,K-ATPASE as Therapeutic TargetAnnual Review of Pharmacology and Toxicology, 1988
- Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridinesJournal of Medicinal Chemistry, 1985